volume 2 | issue 5 | DECEMBER 2012 http://www.kidney-international.org Official Journal of the International Society of Nephrology KDIGOClinicalPracticeGuidelinefortheManagementofBloodPressure inChronicKidneyDisease KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease KDIGO gratefully acknowledges the following consortium of sponsors that make our initiatives possible: Abbott, Amgen, Bayer Schering Pharma, Belo Foundation, Bristol-Myers Squibb, Chugai Pharmaceutical, Coca-Cola Company, Dole Food Company, Fresenius Medical Care, Genzyme, Hoffmann-LaRoche, JC Penney, Kyowa Hakko Kirin, NATCO The Organization for Transplant Professionals, NKF-Board of Directors, Novartis, Pharmacosmos, PUMC Pharmaceutical, Robert and Jane Cizik Foundation, Shire, Takeda Pharmaceutical, Transwestern Commercial Services, Vifor Pharma, and Wyeth. Sponsorship Statement: KDIGO is supported by a consortium of sponsors and no funding is accepted for the development of specific guidelines. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Tables v KDIGO Board Members vi Reference Keys vii Abbreviations and Acronyms viii Notice Foreword Work Group Membership Abstract Summary of Recommendation Statements Chapter 1: Introduction Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients Chapter 3: Blood pressure management in CKD ND patients without diabetes mellitus Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus Chapter 5: Blood pressure management in kidney transplant recipients (CKD T) Chapter 6: Blood pressure management in children with CKD ND Chapter 7: Blood pressure management in elderly persons with CKD ND Chapter 8: Future directions and controversies Methods for Guideline Development Biographic and Disclosure Information Acknowledgments References http://www.kidney-international.org contents & 2012 KDIGO VOL 2 | ISSUE 5 | DECEMBER 2012 TABLES Table 1. Relationship among categories for albuminuria and proteinuria Table 2. Selected calcium-channel blockers Table 3. Questions for future research Table 4. Existing guidelines on ambulatory BP monitoring (ABPM) and home BP monitoring Table 5. 